Why is Mangalam Drugs falling/rising?

As of 17-Jul, Mangalam Drugs and Organics Ltd is experiencing a decline in its stock price, currently at 85.25, which reflects a decrease of 0.65 or 0.76%. The stock has underperformed its sector by 1.18% today and has been on a consecutive downward trend for the last three days, resulting in a total drop of 2.74% during this period. Over the past week, the stock has decreased by 4.21%, while it has shown a modest gain of 4.92% over the past month. However, its year-to-date performance remains concerning, with a significant decline of 26.48%. Despite a very attractive valuation indicated by a ROCE of 8.6 and a PEG ratio of 0.1, the stock's fundamentals are weak, highlighted by a high Debt to EBITDA ratio and a drastic fall in PAT for the recent quarter.
In the broader market context, the Sensex has only declined by 1.12% over the past week, indicating that Mangalam Drugs is underperforming relative to the benchmark. The stock's long-term performance has been consistently poor, with a return of -20.14% over the past year and a staggering -41.55% over three years, contrasting sharply with the Sensex's positive growth of 5.27% year-to-date. This consistent underperformance, coupled with falling investor participation—evidenced by a 63.64% drop in delivery volume—suggests a lack of confidence among investors, further contributing to the stock's recent price decline.